Our lives have been transformed by the information age. But what's coming next is likely to be more profound, call it the genetic information age. We have mapped the human genome and in just the last few years we have learned to read and write DNA like software. And you're about to see a few breakthroughs-in-waiting that would transform human health. For a preview of this revolution in evolution we met George Church, a world leading geneticist, whose own DNA harbors many eccentricities and a few genes for genius.
We found George Church in here.
Cory Smith: Most of these are frozen George. Little bits of George that we have edited all in different tubes.
Church threw himself into his work, literally. His DNA is in many of the experiments in his lab at Harvard Medical School. The fully assembled George Church is 6'5" and 65. He helped pioneer mapping the human genome and editing DNA. Today, his lab is working to make humans immune to all viruses, eliminate genetic diseases, and reverse the effects of time.
Scott Pelley: One of the things your lab is working on is reversing aging.
George Church: That's right.
Scott Pelley: How is that possible?
George Church: Reversing aging is one of these things that is easy to dismiss to say either we don't need it or is impossible or both.
Scott Pelley: Oh, we need it.
George Church: Okay. We need it. That's good. We can agree on that. Well, aging reversal is something that's been proven about eight different ways in animals where you can get, you know, faster reaction times or, you know, cognitive or repair of damaged tissues.
Scott Pelley: Proven eight different ways. Why isn't this available?
George Church: It is available to mice.
In lucky mice, Church's lab added multiple genes that improved heart and kidney function and levels of blood sugar. Now he's trying it in spaniels.
Scott Pelley: So is this gene editing to achieve age reversal?
George Church: This is adding genes. So, it's not really editing genes. It's, the gene function is going down, and so we're boosting it back up by putting in extra copies of the genes.
Scott Pelley: What's the time horizon on age reversal in humans?
George Church: That's in clinical trials right now in dogs. And so, that veterinary product might be a couple years away and then that takes another ten years to get through the human clinical trials.
Human trials of a personal kind made George Church an unlikely candidate to alter human evolution. Growing up in Florida, Church was dyslexic, with attention deficit, and frequently knocked out by narcolepsy.
Scott Pelley: What was it that made you imagine that you could be a scientist?
George Church: The thing that got me hooked was probably the New York World's Fair in 1964. I thought this is the way we should all be living. When I went back to Florida, I said, "I've been robbed," you know? "Where is it all?" So, I said, "Well, if they're not going to provide it, then I'm gonna provide it for myself."
With work and repetition, he beat his disabilities and developed a genius for crystallography, a daunting technique that renders 3D images of molecules through X-rays and math. But in graduate school at Duke, at the age of 20, his mania for the basic structures of life didn't leave time for the basic structure of life.
Scott Pelley: You were homeless for a time.
George Church: Yeah. Briefly.
Scott Pelley: Six months.
George Church: Six months.
Scott Pelley: And where were you sleeping when you were homeless?
George Church: Well, yeah. I wasn't sleeping that much. I was mostly working. I'm narcoleptic. So, I fall asleep sitting up anyway.
His devotion to crystallography was his undoing at Duke.
George Church: I was extremely excited about the research I was doing. And so, I would put in 100-plus hours a week on research and then pretty much didn't do anything else.
Scott Pelley: Not go to class.
George Church: I wouldn't go to class. Yeah.
Duke kicked him out with this letter wishing him well in a field other than biology. But, it turned out, Harvard needed a crystallographer. George Church has been here nearly 40 years. He employs around 100 scientists, about half-and-half men and women.
Scott Pelley: Who do you hire?
George Church: I hire people that are self-selecting, they see our beacon from a distance away. There are a lot of people that are a little, you know, might be considered a little odd. "Neuroatypicals," some of us are called.
Scott Pelley: "Neuroatypical?"
George Church: Right.
Scott Pelley: Unusual brains?
George Church: Right, yeah.
Parastoo Khoshakhlagh: One thing about George that is very significant is that he sees what you can't even see in yourself.
Parastoo Khoshakhlagh and Alex Ng are among the "neuroatypicals." They're engineering human organ tissue.
Cory Smith: I think he tries to promote no fear of failure. The only fear is not to try at all.
Cory Smith's project sped up DNA editing from altering three genes at a time to 13,000 at a time. Eriona Hysolli went to Siberia with Church to extract DNA from the bones of wooly mammoths. She's editing the genes into elephant DNA to bring the mammoth back from extinction.
Eriona Hysolli: We are laying the foundations, perhaps, of de-extinction projects to come.
Scott Pelley: De-extinction.
Eriona Hysolli: Yes.
Scott Pelley: I'm not sure that's a word in the dictionary yet.
Eriona Hysolli: Well, if it isn't, it should be.
Scott Pelley: You know there are people watching this interview who think that is playing God.
George Church: Well, it's playing engineer. I mean, humans have been playing engineer since the dawn of time.
Scott Pelley: The point is, some people believe that you're mucking about in things that shouldn't be disturbed.
George Church: I completely agree that we need to be very cautious. And the more powerful, or the more rapidly-moving the technology, the more cautious we need to be, the bigger the conversation involving lots of different disciplines, religion, ethics, government, art, and so forth. And to see what it's unintended consequences might be.
Church anticipates consequences with a full time ethicist in the lab and he spends a good deal of time thinking about genetic equity. Believing that genetic technology must be available to all, not just those who can afford it.
We saw one of those technologies in the hands of Alex Ng and Parastoo Khoshakhlagh. They showed us what they call "mini-brains," tiny dots with millions of cells each. They've proven that cells from a patient can be grown into any organ tissue, in a matter of days, so drugs can be tested on that patient's unique genome.
Scott Pelley: You said that you got these cells from George's skin? How does that work?
Alex Ng: We have a way to reprogram essentially, skin cells, back into a stem cell state. And we have technologies where now we can differentiate them into tissue such as brain tissue.
Scott Pelley: So you went from George's skin cells, turned those into stem cells, and turned those into brain cells.
Alex Ng: Exactly. Exactly.
Scott Pelley: Simple as that.
Organs grown from a patient's own cells would eliminate the problem of rejection. Their goal is to prove the concept by growing full sized organs from Church's DNA.
George Church: It's considered more ethical for students to do experiments on their boss than vice versa and it's good to do it on me rather than some stranger because I'm as up to speed as you can be on the on the risks and the benefits. I'm properly consented. And I'm unlikely to change my mind.
Alex Ng: We have a joke in the lab, I mean, at some point, soon probably, we're going to have more of his cells outside of his body than he has himself.
Church's DNA is also used in experiments designed to make humans immune to all viruses.
George Church: We have a strategy by which we can make any cell or any organism resistant to all viruses by changing the genetic code. So if you change that code enough you now get something that is resistant to all viruses including viruses you never characterized before.
Scott Pelley: Because the viruses don't recognize it anymore?
George Church: They expect a certain code provided by the host that they replicate in. the virus would have to change so many parts of its DNA or RNA so that it can't change them all at once. So, it's not only dead. But it can't mutate to a new place where it could survive in a new host.
Yes, he's talking about the cure for the common cold and the end of waiting for organ transplants. It's long been known that pig organs could function in humans. Pig heart valves are routinely transplanted already. But pig viruses have kept surgeons from transplanting whole organs. Church's lab altered pig DNA and knocked out 62 pig viruses.
Scott Pelley: What organs might be transplanted from a pig to a human?
George Church: Heart, lung, kidney, liver, intestines, various parts of the eye, skin. All these things.
Scott Pelley: What's the time horizon on transplanting pig organs into human beings?
George Church: you know, two to five years to get into clinical trials. And then again it could take ten years to get through the clinical trials.
Church is a role model for the next generation. He has co-founded more than 35 startups. Recently, investors put $100 million into the pig organ work. Another Church startup is a dating app that compares DNA and screens out matches that would result in a child with an inherited disease.
George Church: You wouldn't find out who you're not compatible with. You'll just find out who you are compatible with.
Scott Pelley: You're suggesting that if everyone has their genome sequenced and the correct matches are made, that all of these diseases could be eliminated?
George Church: Right. It's 7,000 diseases. It's about 5% of the population. It's about a trillion dollars a year, worldwide.
Church sees one of his own genetic differences as an advantage. Narcolepsy lulls him several times a day. But he wakes, still in the conversation, often, discovering inspiration in his twilight zone.
Scott Pelley: If somebody had sequenced your genome some years ago, you might not have made the grade in some way.
George Church: I mean, that's true. I would hope that society sees the benefit of diversity not just ancestral diversity, but in our abilities. There's no perfect person.
Despite imperfection, Church has co-authored 527 scientific papers and holds more than 50 patents. Proof that great minds do not think alike.
The best science can tell, it was about 4 billion years ago that self-replicating molecules set off the spark of biology. Now, humans hold the tools of evolution, but George Church remains in awe of the original mystery: how chemistry became life.
Scott Pelley: Is the most amazing thing about life, then, that it happened at all?
George Church: It is amazing in our current state of ignorance. We don't even know if it ever happened ever in the rest of the universe. it's awe-inspiring to know that it either happened billions of times, or it never happened. Both of those are mind boggling. It's amazing that you can have such complex structures that make copies of themselves. But it's very hard to do that with machines that we've built. So, we're engineers. But we're rather poor engineers compared to the pseudo engineering that is biological evolution.
Produced by Henry Schuster. Associate producer, Rachael Morehouse. Broadcast associate, Ian Flickinger.
Read more from the original source:
Harvard geneticist George Church's goal: to protect humans from viruses, genetic diseases, and aging - 60 Minutes - CBS News
- Stem Cell Banking Market smart Strategies of the Research and Development Process Dagoretti News - Dagoretti News - January 23rd, 2020
- Meet the Culprits of Cell Culture Contamination - Technology Networks - January 23rd, 2020
- What Will Be The Growth of Animal Stem Cell Therapy Market? Dagoretti News - Dagoretti News - January 23rd, 2020
- Biobanks Market To Witness An Impressive Growth During The Forecast Period 2017 2025 Dagoretti News - Dagoretti News - January 23rd, 2020
- Stem Cell Alopecia Treatment Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 - Vital News 24 - January 23rd, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - India Education Diary - January 23rd, 2020
- Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy - January 23rd, 2020
- BrainStorm Cell Therapeutics COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit - Yahoo Finance - January 22nd, 2020
- Neurogenesis could be a therapeutic target in neurodegenerative disease - Drug Target Review - January 22nd, 2020
- Getting to the Root of the Disease: Developing Drugs Against the Hard-to-Target Wnt Pathway - BioSpace - January 22nd, 2020
- Animal Stem Cell Therapy Market Global and Regional Analysis by Top Key Market Players, Key Regions, Product Segments, and Applications 2024 ... - January 22nd, 2020
- At 35.7% CAGR, Animal Stem Cell Therapy Market Size will reach 108.3 million USD by 2025 - MENAFN.COM - January 22nd, 2020
- Global Cholangiocarcinoma Therapeutics Market 2019-2023 | Evolving Opportunities with Bristol-Myers Squibb Company and Eli Lilly and Company |... - January 22nd, 2020
- 1000 Entrepreneurs: Ken Aldrich on 30 Years of Venture Capital and 50 Successful Businesses - GuruFocus.com - January 22nd, 2020
- Preparing the youth - The News International - January 22nd, 2020
- Canine Stem Cell Therapy Market Extensive Growth Opportunities to Be Witnessed by 2019-2026 - Fusion Science Academy - January 22nd, 2020
- Cell Separation Technologies Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 2026 - Dagoretti News - January 22nd, 2020
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 - January 21st, 2020
- Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com - January 21st, 2020
- Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies - Healio - January 21st, 2020
- Could Scientists 'Hack' the Zika Virus to Kill Brain Cancer? - Livescience.com - January 20th, 2020
- Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti... - January 20th, 2020
- Stem Cell Cartilage Regeneration Market Report 2019:2026 Industry Growth Forecasts by Manufacturers, Countries, Type and Application Dagoretti News... - January 20th, 2020
- Market opportunity and growth drivers of Cell Separation Technology Market till 2025 Dagoretti News - Dagoretti News - January 20th, 2020
- Stem Cell Research: Uses, Types & Examples - January 19th, 2020
- Stem Cell Assay Market expected to Witness a Sustainable Growth over 2016 2024 Dagoretti News - Dagoretti News - January 19th, 2020
- 2D Cell Culture Market to Witness Growth Acceleration During 2020 to 2026 Dagoretti News - Dagoretti News - January 19th, 2020
- Stem Cell and Progenitor Cell-based therapeutics Market 2020 Share Growing Rapidly with Recent Trends, Growth, Size, Share, Clinical Review,... - January 18th, 2020
- Animal Stem Cell Therapy Market Poised to Garner Maximum Revenues During 2017 2025 Dagoretti News - Dagoretti News - January 18th, 2020
- Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies - Yahoo... - January 18th, 2020
- Universities aren't making a lot of money from university research - The Hechinger Report - January 18th, 2020
- R&D Activities to Fast-track the Growth of the Biobanks Market Between 2017 2025 Dagoretti News - Dagoretti News - January 18th, 2020
- Rheumatoid Arthritis Stem Cell Therapy Market Latest Innovations, Drivers and Industry Key Events 2018 to 2028 - Fusion Science Academy - January 18th, 2020
- Heart Cell Research Leads to Discovery That May Lead to Unreliable Data - Newswise - January 17th, 2020
- Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2019 Valuable Growth Prospects and Upcoming Trends till 2024 Dagoretti News... - January 17th, 2020
- In Vitro Lung Model Market to 2027 Increasing Adoption Of 3D Model Systems - PharmiWeb.com - January 17th, 2020
- Curcumin Combined with Thalidomide Reduces Expression of STAT3 and Bcl | DDDT - Dove Medical Press - January 15th, 2020
- Global Stem Cell Reconstructive Market 2019 Share, Trend, Segmentation and Forecast to 2025 - Instanews247 - January 15th, 2020
- The Checkout: Powering Plant and Cell-based Innovations - NOSH - January 11th, 2020
- Cultured Meat Startup New Age Meats Secures $2.7M in Seed Round - vegconomist - the vegan business magazine - January 11th, 2020
- Stem Cell Gun Devices Market Projected to Witness Vigorous Expansion by 2019 2027 - Food & Beverage Herald - January 11th, 2020
- Stem Cell Manufacturing Market Size, Top Companies, Business Opportunities and Growth 2020 to 2027 - Pro News Time - January 11th, 2020
- TEDCO funds open again for applications - Maryland Daily Record - January 4th, 2020
- Cell Culture Protein Surface Coating Market Competitive Environment and Higher Growth Rate with Forecast to 2025 - Filmi Baba - January 4th, 2020
- Stem Cell Alopecia Treatment Market Segmentation, Top Companies, Applications, Comprehensive Research Report and Forecast to 2026 - Market Research... - December 30th, 2019
- Animal Stem Cell Therapy Market Research Report 2026 Observational Studies With Top Manufacturers - Market Research Sheets - December 30th, 2019
- Stem Cell Cartilage Regeneration Market Key players, Geographical Regions and Growth Analysis Outlook Up To 2028 - Sound On Sound Fest - December 30th, 2019
- Scientists race to use zero gravity to kill the worst cancers - Big Think - December 30th, 2019
- How technology has changed the world in the last decade - The Upcoming - December 30th, 2019
- Stem Cell Market Analysis, Growth By Top Companies, Trends By Types And Application, Forecast Analysis To 2027 - Market Research Sheets - December 30th, 2019
- Don't throw food in the trash in Vermont, or ask about salary history in New Jersey. Here are 7 state law changes for 2020 - USA TODAY - December 28th, 2019
- From the image of a black hole to 'artificial embryos', 2019 was the year of many firsts in science - Economic Times - December 28th, 2019
- Animal Stem Cell Therapy Market: Challenges and Opportunities Report 2017 2025 Bulletin Line - Bulletin Line - December 28th, 2019
- Protein Associated with Leukemia May Lead to Targeted Therapy for Currently Incurable Acute Lymphoblastic Leukemia - Pharmacy Times - December 25th, 2019
- The Next Generation of Biologic Pacemakers? New Discovery in Stem Cells from Fat Creates Another Alternative Treatment - DocWire News - December 25th, 2019
- Study of the 3D Cell Culture Market in Asia-Pacific, 2019-2027: Projecting a 13.11% CAGR, Driven by Promising Developments Using Regenerative Medicine... - December 24th, 2019
- Stem Cells Market Poised to Expand at a Robust Pace Over 2017 to 2025 - Market Research Sheets - December 24th, 2019
- Illuminating Christmas, 19 years and counting... in honour of the Anthony Nolan Charity - London News Online - December 24th, 2019
- The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018 - Yahoo Finance - December 24th, 2019
- Global and Southeast Asia Embryonic Stem Cell Market 2013-2023 by Top Key Players, YoY Growth, Trends, Size, Share and Revenue Analysis - Market... - December 24th, 2019
- Researchers Create Functional Mini-Liver by 3D Bioprinting - 3D Printing Progress - December 24th, 2019
- FY 2020 Government Funding Bill Repeals ACA Health-Related Taxes, Extends Expiring Health Provisions, Makes Other Health Policy Updates - Lexology - December 24th, 2019
- Making advanced therapies takes industrializing personalization - STAT - December 23rd, 2019
- Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Yahoo... - December 23rd, 2019
- Stem Cell Market SWOT Analysis 2019 | Industry Leading Players by Size, Share, Industry Revenue, and Regional Forecast to 2024 - Ankeny Observer - December 23rd, 2019
- BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID in Relapsed or Refractory Indolent Lymphoma - BioSpace - December 23rd, 2019
- Stem Cell Research & Therapy | Home page - December 18th, 2019
- Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Business... - December 18th, 2019
- 3D Cell Culture Market: Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation - Global Forecast to 2024 - ResearchAndMarkets.com -... - December 18th, 2019
- Functional "Mini-liver" Created By 3D Bioprinting - Technology Networks - December 18th, 2019
- Scientists hope MND cure is a step closer after stem cell breakthrough discovery - The National - December 18th, 2019
- Stem Cell Banking Market: Adopts Innovation to Stay Competitive Forecast - Market Research Sheets - December 18th, 2019
- Stem Cell Discovery Could Transform Treatment of Tendon Injuries - Gilmore Health News - December 18th, 2019
- Attractive Market Opportunities in the Cord Blood Stem Cell Market By 2029 - Sound On Sound Fest - December 17th, 2019
- Attractive Market Opportunities in the Stem Cell Cartilage Regeneration Market By 2029 - Sound On Sound Fest - December 17th, 2019
- Global Stem Cell Media Market |2018-2023| Qualitative & Quantitative Analysis, Key Vendors Analysis, Reliability, Growth Innovation in Technology... - December 17th, 2019
- Global Stem Cell Therapy Market to Become a Worth US$ 4759.27 Million By 2024 - E-Industry News - December 17th, 2019
- Stem Cell Market to 2025 Analysis by Top Vendors - Space Market Research - December 17th, 2019
- Start-up to research on degenerative eye disease - Deccan Herald - December 8th, 2019
- R&D Activities to Fast-track the Growth of the Stem Cell Assay Market Between 2018 2028 - Kentucky Reports - December 8th, 2019